Kits Eyecare Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St

March 06, 2025

Kits Eyecare (TSE:KITS) Full Year 2024 Results

Key Financial Results

Revenue: CA$159.3m (up 32% from FY 2023).
Net income: CA$3.12m (up from CA$2.22m loss in FY 2023).
Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
EPS: CA$0.099 (up from CA$0.071 loss in FY 2023).

earnings-and-revenue-growth — TSX:KITS Earnings and Revenue Growth March 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kits Eyecare EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 145%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Specialty Retail industry in Canada.

Performance of the Canadian Specialty Retail industry.

The company's shares are up 6.6% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Kits Eyecare's balance sheet health.

If you're looking to trade Kits Eyecare, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Kits Eyecare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.